Loading clinical trials...
Loading clinical trials...
SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are currently off lipid-modifying therapy. This was a prospective, randomized, open-label, blinded endpoint (PROBE) study.
Age
21 - No limit years
Sex
ALL
Healthy Volunteers
No
Anaheim, California, United States
Huntington Park, California, United States
Long Beach, California, United States
Sacramento, California, United States
Walnut Creek, California, United States
Brooksville, Florida, United States
Daytona Beach, Florida, United States
Gainesville, Florida, United States
Largo, Florida, United States
Merritt Island, Florida, United States
Start Date
April 1, 2007
Primary Completion Date
February 1, 2008
Last Updated
June 13, 2011
199
ACTUAL participants
Niacin ER/Simvastatin Tablets
DRUG
atorvastatin
DRUG
Lead Sponsor
Abbott
NCT06062394
NCT07230730
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07334834